Halo Labs Inc. - CEO, Kiran Sidhu
CEO, Kiran Sidhu
Source: The Dales Report
  • Cannabis company Halo Labs (NEO:HALO) has reported a 158 per cent revenue increase for the year ending December 31, 2019
  • This comes despite upsets related to health concerns in the US vaping market
  • Gross profit for 2019 came in at C$4.35 million, compared to a loss of $420,000 in 2018
  • Operating expenses for 2019 also increased to $37.89 million from $13.62 million the year before
  • Halo Labs (HALO) is up 1.85 per cent to 13.75 cent per share, with a market cap of $52 million

Cannabis company Halo Labs (NEO:HALO) has reported a 158 per cent revenue increase for the year ending December 31, 2019.

The cannabis cultivator, manufacturer, and distributor reported total revenue of C$39.44 million for the year. In 2018, the company reported a total revenue of $15.3 million.

Gross profit also improved to $4.35 million, compared to a loss of $420,000 the year before.

Halo Labs says that the improved financial performance is partly due to contributions from new operations in the Californian market.

The promising results came even in the face of vape-related upsets. In the latter half of the year, concerns grew regarding the potential health impacts of such products.

A vape-inflicted lung injury outbreak, known as EVALI (e-cigarette/vaping associated lung injury), impacted sales. In fact, it resulted in many cities and states in the US banning the sale of vaporisers.

Halo Labs maintains that it does not use any additives in its cartridges, which is believed to cause EVALI. Nevertheless, the negative public perception of the products culminated in reduced sales and product returns.

The bans have since lifted, and Halo Labs has now resumed the sale of its vaporiser products.

In addition to revenue and profit increases, operating expenses for 2019 also grew to $37.89 million. They were only $13.62 million in the year before.

The company says that this is primarily attributable to an increase in professional fees related to financing, merger and acquisition support. Halo Labs also noted that expansion efforts in California and Nevada further pushed general and salary-based costs.

Looking forward, Halo Labs says that it will continue to acquire distressed assets, to expand the company’s operating footprint. Where possible, Halo Labs also plans to pay some senior management figures in stock, to preserve liquidity.

Halo Labs (HALO) is up 1.85 per cent to 13.75 cent per share at 1:42pm EST.

More From The Market Online
Cannabis Report image of farmed cannabis plants

The Market Online’s Weekly Cannabis Report – July 26, 2024

Tilray Oral Solution THC10:CBD10 cannabis extract, aka Tilray Solução Oral THC10:CBD10, has been approved for medical use in Portugal.
medical branch logo

Tilray approved for third medical cannabis product in Portugal

Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal.